$56M Raised to Roll Out Nerve-Stimulation Device for Post-Amputation Pain Relief
In a rush? Read the summary:
Neuros Medical has raised $56 million in Series D funding to support the U.S. launch of Altius®, the first FDA-approved nerve stimulation device for post-amputation pain relief. Altius® offers a non-opioid, on-demand treatment that targets peripheral nerves with precise electrical pulses, providing chronic pain relief for amputees. With nearly 2 million Americans living with limb loss, this breakthrough technology addresses a critical need in pain management while empowering patients to control pain episodes without medication.
———
Reading Time: 3 minutes
A new hope for post-amputation pain emerges as Neuros Medical, a U.S.-based medical device company, secures $56 million in Series D funding to support the U.S. launch of Altius®. This device is the first and only FDA-approved nerve stimulation treatment designed to target uncontrollable pain after limb loss.
The funding round, co-led by EQT Life Sciences through its LSP 7 fund and the EQT Health Economics strategy, reflects strong investor confidence in the transformative potential of the Altius® system. Funds will be used to expand commercial operations and make this groundbreaking therapy available to more patients nationwide.
Tackling an Urgent, Underserved Need
Chronic post-amputation pain affects up to 80% of amputees in the U.S., and many have limited treatment options, especially those avoiding opioids. Altius® provides a non-opioid alternative: an implantable device that delivers precise electrical stimulation to peripheral nerves near the amputation site. Patients can activate it when needed, usually in 30-minute sessions when pain flares up.
Neuros Medical’s president and CEO, David Veino, said that the funding allows the company to improve access to its innovative non-opioid treatment for a highly underserved patient group. He emphasized that this development aligns with the company’s goal to “relieve pain and restore life for amputees.”
On-Demand Pain Relief
Unlike traditional pain relief options, like medications or nerve blocks, Altius® empowers users with control. It features a cuff electrode and an implantable pulse generator. With just a press of a button, users can activate a therapeutic electrical signal to block pain at the source.
EQT Life Sciences Partner Fouad Azzam, Ph.D., described it as a game changer. He noted that Neuros Medical is tackling a critical and often overlooked issue in chronic pain care and expressed the belief that Altius® can greatly enhance the quality of life for amputees.
What This Means for Amputees
For years, individuals suffering from chronic post-amputation pain have depended on medications, mirror therapy, or invasive procedures to control residual limb and phantom limb pain. Altius® presents a significant step forward—a non-drug, precisely targeted, customizable option that can be used as needed.
With nearly 2 million people living with limb loss in the U.S. and around 300,000 new amputations each year, effective and sustainable pain relief is essential. Neuros Medical’s technology provides a solution that empowers patients rather than sedates them.
Looking Ahead
Now that the FDA approval has been secured, the upcoming commercial launch is a significant milestone. The company’s mission, “to relieve pain and restore life,” is transitioning from a vision to reality for amputees nationwide.
To learn more about Altius® and stay updated on availability, visit www.neurosmedical.com.
Related Reading:
Different Types of Post-Amputation Pain
